Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Mental Health Strategy 2024-2030

Executive Summary
 
We can all play a role in promoting and safeguarding mental health for all population groups and in supporting individuals going through difficult times. This strategy serves as a seven-year roadmap aimed at guiding the Ministry of Public Health and all relevant stakeholders while mobilizing efforts to improve mental health in Lebanon. In Lebanon, in particular, improving mental health also requires addressing the social, economic, and political factors that negatively impact mental well-being and hinder the recovery process.
 
The strategy was developed using a comprehensive approach to address key issues. First, an assessment of the mental health situation in the country was conducted, including the burden of diseases, needs, and an evaluation of the existing system’s ability to meet these needs. Previous efforts were also reviewed to identify areas that need to be maintained and those requiring improvement. Furthermore, consultations were held with experts and local stakeholders, including individuals with lived experiences, to help set strategic priorities. The strategy was also guided by international frameworks, including World Health Organization (WHO) guidelines and other evidence-based recommendations. Special care was taken to select approaches that are appropriate and adaptable to the local context. Finally, the strategy was published and made available to the public for feedback and revisions.
 
The strategy addresses all fundamental aspects of the mental health system to enhance overall mental well-being and prevent mental disorders, with a focus on the following key areas:
  • Raising awareness about mental health, reducing misconceptions, and implementing evidence-based interventions to prevent mental health issues. This includes emphasizing the importance of addressing political, social, and economic factors that influence mental health.
  • Empowering individuals by providing them with the resources, knowledge, and skills necessary to protect their mental well-being and ensuring access to available services when needed.
  • Ensuring that individuals with mental health disorders can access high-quality care whenever they need it, regardless of their place of residence.
  • Supporting healthcare providers and all professionals in the field by building their capacity based on evidence-based practices and helping them safeguard their own mental health.
  • Preventing and reducing harmful practices that violate human rights and quality standards in the provision of mental health services.
  • Enhancing data availability and conducting valuable research to guide and support efforts to improve mental health across the country.
  • Establishing legal frameworks, policies, and appropriate funding mechanisms to strengthen the mental health system.
  • Integrating the views, perspectives, and preferences of individuals with lived experiences in the design, development, and implementation of services, policies, and practices.
Specific actions have been planned for each of these key areas to ensure the necessary improvements in the country.
 

 
National Mental Health Strategy 2024-2030 (Please click on this link to download the document)
 
Theory of Change Map (Please click on this link to download the document)

Executive Summary (English, French, Arabic) 
 
    ...
    49
    ...
ATC Name B/G Ingredients Dosage Form Price
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 5mg Tablet 3,867,041 L.L
B01AC27 UPTRAVI B Selexipag - 1400mcg 1400mcg Tablet, film coated 275,097,581 L.L
N02BF02 LYRICA B Pregabalin - 75mg 75mg Capsule 2,131,334 L.L
N06DX01 EBIXA B Memantine - 20mg 20mg Tablet, film coated 4,004,651 L.L
S01EE04 TRAVATAN B Travoprost - 40mcg/ml 0.004% Drops solution 806,306 L.L
B01AC27 UPTRAVI B Selexipag - 1600mcg 1600mcg Tablet, film coated 275,097,581 L.L
C01EA01 PROSTIN VR B Alprostadil - 500mcg/ml 500mcg/ml Injectable concentrated solution 19,894,577 L.L
J01EE01 BACTRIM FORTE B Trimethoprim - 160mg, Sulfamethoxazole - 800mg Tablet 344,024 L.L
M04AA03 ADENURIC B Febuxostat - 80mg 80mg Tablet, film-scored 2,127,111 L.L
N02BF02 LYRICA B Pregabalin - 75mg 75mg Capsule 598,010 L.L
L01ED05 LORBRENA B Lorlatinib - 100mg 100mg Tablet L.L
A04AA55 AKYNZEO B Palonosetron - 0.5mg, Netupitant - 300mg Capsule, hard 7,364,372 L.L
C09AA05 TRITACE B Ramipril - 5mg 5mg Tablet 509,316 L.L
N05AX08 RISPERDAL B Risperidone - 1mg/ml 1mg/ml Solution 1,377,439 L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated L.L
A04AD GRAVOL B Dimenhydrinate - 15mg/5ml 15mg/5ml Liquid 258,018 L.L
C01EB15 VASTAREL B Trimetazidine - 35mg 35mg Tablet, film coated, modified release 1,053,573 L.L
D06BX01 ROZEX B Metronidazole - 0.75g/100g 0.75% Gel 584,571 L.L
L01CX01 YONDELIS B Trabectedin - 1mg 1mg Injectable powder for solution 126,536,515 L.L
N05AX08 RISPERDAL B Risperidone - 1mg/ml 1mg/ml Solution 1,377,439 L.L
R03DX10 FASENRA B Benralizumab - 30mg 30mg Injectable solution 214,213,273 L.L
A04AD GRAVOL B Dimenhydrinate - 50mg 50mg Tablet 163,949 L.L
A10BD15 XIGDUO XR B Metformin HCl XR - 1000mg, Dapagliflozin - 10mg Tablet 3,006,579 L.L
J01FA02 ROVAMYCINE B Spiramycin - 3MIU 3MIU Tablet, film coated 649,076 L.L
L04AX04 REVLIMID B Lenalidomide - 15mg 15mg Capsule 116,241,703 L.L
S01EE06 VYZULTA B Latanoprostene bunod - 0.024% 0.024% Solution 1,948,572 L.L
A04AD GRAVOL B Dimenhydrinate - 100mg 100mg Suppository 294,302 L.L
B01AE07 PRADAXA B Dabigatran etexilate (mesilate) - 110mg 110mg Capsule, hard 1,603,204 L.L
C01EB17 PROCORALAN B Ivabradin (HCl) - 5mg 5mg Tablet, film coated 1,890,786 L.L
J01FA02 ROVAMYCINE B Spiramycin - 1.5MIU 1.5MIU Tablet, film coated 256,674 L.L
    ...
    49
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025